SCHEMBL2867928

SCHEMBL2867928

O=C(NCc1ccco1)c1ccc2[nH]nc(-c3cccc(F)c3)c2c1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.62
MAPK1 P28482 7/20 0.52
TTK P33981 4/20 0.52
MAPK3 P27361 5/20 0.52
CSNK1D P48730 1/20 0.52
POLB P06746 4/20 0.51
NPC1 O15118 2/20 0.51
MEN1 O00255 1/20 0.51
PKM P14618 1/20 0.51
KMT2A Q03164 1/20 0.51
ALDH1A1 P00352 2/20 0.50
TSHR P16473 2/20 0.49
RECQL P46063 1/20 0.49
MAPK8 P45983 1/20 0.49
TP53 P04637 1/20 0.48
MAPT P10636 1/20 0.48
RAB9A P51151 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4327002 0.85 HPGD (0.58) HPGDMAPK1POLBNPC1MEN1
SCHEMBL4328143 0.85 HPGD (0.53) HPGDMAPK1POLBNPC1MEN1
SCHEMBL4340981 0.85 HPGD (0.52) HPGDMAPK1POLBNPC1MEN1
SCHEMBL4336101 0.85 HPGD (0.57) HPGDMAPK1POLBNPC1MEN1
SCHEMBL13927641 0.83 HPGD (0.52) HPGDMAPK1POLBNPC1MEN1
SCHEMBL4334956 0.82 HPGD (0.53) HPGDPOLBNPC1MEN1PKM
SCHEMBL4329145 0.82 HPGD (0.48) HPGDPOLBNPC1MEN1KMT2A
SCHEMBL4339183 0.79 HPGD (0.48) HPGDMAPK1POLBNPC1MEN1
SCHEMBL2862134 0.79 CSNK1D (0.54) MAPK1TTKMAPK3CSNK1D
SCHEMBL2870086 0.78 KDM4E (0.54) HPGDMAPK1TTKMAPK3CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
CN-1300116-C 1H-indazole compounds EISAI CO LTD (JP) 2007-02-14 CN disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed
CN-1512987-A Novel 1H-indazole compound ������������ʽ���� 2004-07-14 CN disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 HPGD 1817/4885MAPK1 1/4885TTK 1201/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 HPGD 1866/4885MAPK1 1/4885TTK 1066/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 HPGD 1817/4885MAPK1 1/4885TTK 1201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.